Oncology

Sanofi and BioNTech Enter an Up to $1.58 Billion Immuno-Oncology Partnership

PARIS and MAINZ, Germany, November 3, 2015 /PRNewswire via COMTEX/ — Sanofi and BioNTech A.G. today announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to …

Read More »

FDA Grants Breakthrough Therapy Designation to Merck’s Keytruda for Treatment of Colorectal Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA®(pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is …

Read More »

EC Approves Celgene’s Vidaza for Treatment of AML

BOUDRY, Switzerland–(BUSINESS WIRE)– Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that theEuropean Commission (EC) has approved VIDAZA® (azacitidine for injection) for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell …

Read More »

Daiichi Sankyo’s Rare Cancer Drug Receives Breakthrough Therapy Designation from the FDA

Parsippany, NJ and Berkeley, CA – (October 30, 2015) – Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational oral CSF-1R inhibitor pexidartinib (formerly PLX3397) for the treatment …

Read More »

Igenica Partners with MedImmune to Research Anti-SAIL ADCs

BURLINGAME, Calif.–(BUSINESS WIRE)–Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative antibody-based therapies for the treatment of cancer, announced today that it has entered into an oncology research agreement with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN). Igenica and MedImmune will …

Read More »

Natera’s mmPCR Technology Successfully Identified breast Cancer in Study

SAN CARLOS, Calif., Oct. 28, 2015 /PRNewswire/ — Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in the October 2015 issue of Translational Oncology showing that Natera’s massively multiplexed PCR (mmPCR) technology and proprietary analytic methodologies can detect …

Read More »

FDA Approves Amgen’s Imlygic as First Oncolytic Viral Therapy in the US

THOUSAND OAKS, Calif., Oct. 27, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in …

Read More »